Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

van Leeuwen, F.W. Schottelius, M. Mottaghy, F.M. Hyafil, F. Lubberink, M. Kramer-Marek, G. Oyen, W.J. (2022). Perspectives on translational molecular imaging and therapy: an overview of key questions to be addressed. , Vol.12 (1), p. 31.

Da Pieve, C. Costa Braga, M. Turton, D.R. Valla, F.A. Cakmak, P. Plate, K.-. Kramer-Marek, G. (2022). New Fully Automated Preparation of High Apparent Molar Activity 68Ga-FAPI-46 on a Trasis AiO Platform. Molecules (basel, switzerland), Vol.27 (3).  show abstract

Lampis, A. Hahne, J.C. Gasparini, P. Cascione, L. Hedayat, S. Vlachogiannis, G. Murgia, C. Fontana, E. Edwards, J. Horgan, P.G. Terracciano, L. Sansom, O.J. Martins, C.D. Kramer-Marek, G. Croce, C.M. Braconi, C. Fassan, M. Valeri, N. (2021). MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. Cell death and differentiation, .  show abstract

Turnock, S. Turton, D.R. Martins, C.D. Chesler, L. Wilson, T.C. Gouverneur, V. Smith, G. Kramer-Marek, G. (2020). 18F-meta-fluorobenzylguanidine (18F-mFBG) to monitor changes in norepinephrine transporter expression in response to therapeutic intervention in neuroblastoma models. Scientific reports, Vol.10 (1), pp. 20918-?.  show abstract

Mączyńska, J. Da Pieve, C. Burley, T.A. Raes, F. Shah, A. Saczko, J. Harrington, K.J. Kramer-Marek, G. (2020). Immunomodulatory activity of IR700-labelled affibody targeting HER2. Cell death & disease, Vol.11 (10), pp. 886-?.  show abstract

Da Pieve, C. Makarem, A. Turnock, S. Maczynska, J. Smith, G. Kramer-Marek, G. (2020). Thiol-Reactive PODS-Bearing Bifunctional Chelators for the Development of EGFR-Targeting [18F]AlF-Affibody Conjugates. Molecules (basel, switzerland), Vol.25 (7).  show abstract

Burley, T.A. Da Pieve, C. Martins, C.D. Ciobota, D.M. Allott, L. Oyen, W.J. Harrington, K.J. Smith, G. Kramer-Marek, G. (2019). Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models. Journal of nuclear medicine : official publication, society of nuclear medicine, Vol.60 (3), pp. 353-361.  show abstract

Stowe, C.L. Burley, T.A. Allan, H. Vinci, M. Kramer-Marek, G. Ciobota, D.M. Parkinson, G.N. Southworth, T.L. Agliardi, G. Hotblack, A. Lythgoe, M.F. Branchini, B.R. Kalber, T.L. Anderson, J.C. Pule, M.A. (2019). Near-infrared dual bioluminescence imaging in mouse models of cancer using infraluciferin. Elife, Vol.8.  show abstract

Baker, L.C. Sikka, A. Price, J.M. Boult, J.K. Lepicard, E.Y. Box, G. Jamin, Y. Spinks, T.J. Kramer-Marek, G. Leach, M.O. Eccles, S.A. Box, C. Robinson, S.P. (2018). Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma. Frontiers in oncology, Vol.8, pp. 271-?.  show abstract

Martins, C.D. Kramer-Marek, G. Oyen, W.J. (2018). Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges. Expert opinion on drug delivery, Vol.15 (2), pp. 185-196.  show abstract

Martins, C.D. Da Pieve, C. Burley, T.A. Smith, R. Ciobota, D.M. Allott, L. Harrington, K.J. Oyen, W.J. Smith, G. Kramer-Marek, G. (2018). HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. Clinical cancer research : an official journal of the american association for cancer research, Vol.24 (8), pp. 1853-1865.  show abstract

King, A. Doepner, A. Turton, D. Ciobota, D.M. Da Pieve, C. Wong Te Fong, A.-. Kramer-Marek, G. Chung, Y.-. Smith, G. (2018). Radiosynthesis of the anticancer nucleoside analogue Trifluridine using an automated 18F-trifluoromethylation procedure. Organic & biomolecular chemistry, Vol.16 (16), pp. 2986-2996.  show abstract

Burley, T.A. Mączyńska, J. Shah, A. Szopa, W. Harrington, K.J. Boult, J.K. Mrozek-Wilczkiewicz, A. Vinci, M. Bamber, J.C. Kaspera, W. Kramer-Marek, G. (2018). Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment. International journal of cancer, Vol.142 (11), pp. 2363-2374.  show abstract

Szopa, W. Burley, T.A. Kramer-Marek, G. Kaspera, W. (2017). Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. Biomed research international, Vol.2017, pp. 8013575-?.  show abstract

Allott, L. Da Pieve, C. Meyers, J. Spinks, T. Ciobota, D.M. Kramer-Marek, G. Smith, G. (2017). Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89. Chemical communications (cambridge, england), Vol.53 (61), pp. 8529-8532.  show abstract

Mansfield, D.C. Kyula, J.N. Rosenfelder, N. Chao-Chu, J. Kramer-Marek, G. Khan, A.A. Roulstone, V. McLaughlin, M. Melcher, A.A. Vile, R.G. Pandha, H.S. Khoo, V. Harrington, K.J. (2016). Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Gene therapy, Vol.23 (4), pp. 357-368.  show abstract

Kramer-Marek, G. Oyen, W.J. (2016). Targeting the Human Epidermal Growth Factor Receptors with Immuno-PET: Imaging Biomarkers from Bench to Bedside. Journal of nuclear medicine : official publication, society of nuclear medicine, Vol.57 (7), pp. 996-1001.

Da Pieve, C. Allott, L. Martins, C.D. Vardon, A. Ciobota, D.M. Kramer-Marek, G. Smith, G. (2016). Efficient [(18)F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors. Bioconjugate chemistry, Vol.27 (8), pp. 1839-1849.  show abstract

Denis-Bacelar, A.M. Cronin, S.E. Da Pieve, C. Paul, R.L. Eccles, S.A. Spinks, T.J. Box, C. Hall, A. Sosabowski, J.K. Kramer-Marek, G. Flux, G.D. (2016). Pre-clinical quantitative imaging and mouse-specific dosimetry for 111In-labelled radiotracers. Ejnmmi research, Vol.6 (1), pp. 85-?.  show abstract

Xu, Z. Bagci, U. Mansoor, A. Kramer-Marek, G. Luna, B. Kubler, A. Dey, B. Foster, B. Papadakis, G.Z. Camp, J.V. Jonsson, C.B. Bishai, W.R. Jain, S. Udupa, J.K. Mollura, D.J. (2015). Computer-aided pulmonary image analysis in small animal models. Medical physics, Vol.42 (7), pp. 3896-3910.

Adesina, S.K. Holly, A. Kramer-Marek, G. Capala, J. Akala, E.O. (2014). Polylactide-based paclitaxel-loaded nanoparticles fabricated by dispersion polymerization: characterization, evaluation in cancer cell lines, and preliminary biodistribution studies. J pharm sci, Vol.103 (8), pp. 2546-2555.  show abstract

Mohd Nafi, S.N. Generali, D. Kramer-Marek, G. Gijsen, M. Strina, C. Cappelletti, M. Andreis, D. Haider, S. Li, J.-. Bridges, E. Capala, J. Ioannis, R. Harris, A.L. Kong, A. (2014). Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget, Vol.5 (15), pp. 5934-5949.  show abstract

Nafi, S. Generali, D. Kramer-Marek, G. Gijsen, M. Strina, C. Cappelletti, M. Andreis, D. Haider, S. Li, J.L. Bridges, E. Capala, J. Ioannis, R. Harris, A.L. Kong, A. (2014). Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget, .  show abstract

Feldinger, K. Generali, D. Kramer-Marek, G. Gijsen, M. Ng, T.B. Wong, J.H. Strina, C. Cappelletti, M. Andreis, D. Li, J.-. Bridges, E. Turley, H. Leek, R. Roxanis, I. Capala, J. Murphy, G. Harris, A.L. Kong, A. (2014). ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget, Vol.5 (16), pp. 6633-6646.  show abstract

Kramer-Marek, G. Gore, J. Korc, M. (2013). Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions. Cancer lett, Vol.341 (2), pp. 132-138.  show abstract

Bagci, U. Kramer-Marek, G. Mollura, D.J. (2013). Automated computer quantification of breast cancer in small-animal models using PET-guided MR image co-segmentation. Ejnmmi res, Vol.3 (1), p. 49.  show abstract

Capala, J. Kong, A. Kramer-Marek, G. Gijsen, M. (2012). Reply. J nucl med, .

Kramer-Marek, G. Gijsen, M. Kiesewetter, D.O. Bennett, R. Roxanis, I. Zielinski, R. Kong, A. Capala, J. (2012). Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J nucl med, Vol.53 (4), pp. 629-637.  show abstract

Kramer-Marek, G. Bernardo, M. Kiesewetter, D.O. Bagci, U. Kuban, M. Aras, O. Zielinski, R. Seidel, J. Choyke, P. Capala, J. (2012). PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG. J nucl med, Vol.53 (6), pp. 939-946.  show abstract

Kramer-Marek, G. Capala, J. (2012). The role of nuclear medicine in modern therapy of cancer. Tumor biology, Vol.33 (3), pp. 629-640.

Mitsunaga, M. Nakajima, T. Sano, K. Kramer-Marek, G. Choyke, P.L. Kobayashi, H. (2012). Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy. Bmc cancer, Vol.12, p. 345.  show abstract

Kramer-Marek, G. Longmire, M.R. Choyke, P.L. Kobayashi, H. (2012). Recent Advances in Optical Cancer Imaging of EGF Receptors. Current medicinal chemistry, Vol.19 (28), pp. 4759-4766.

Jagoda, E.M. Lang, L. Bhadrasetty, V. Histed, S. Williams, M. Kramer-Marek, G. Mena, E. Rosenblum, L. Marik, J. Tinianow, J.N. Merchant, M. Szajek, L. Paik, C. Cecchi, F. Raffensperger, K. Jose-Dizon, J.-. Bottaro, D.P. Choyke, P. (2012). Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. J nucl med, Vol.53 (10), pp. 1592-1600.  show abstract

Kramer-Marek, G. Capala, J. (2012). Can PET imaging facilitate optimization of cancer therapies?. Curr pharm des, Vol.18 (18), pp. 2657-2669.  show abstract

Dahl, M. Bouchelouche, P. Kramer-Marek, G. Capala, J. Nordling, J. Bouchelouche, K. (2011). Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. Molecular biology reports, Vol.38 (7), pp. 4237-4243.

Kramer-Marek, G. Shenoy, N. Seidel, J. Griffiths, G.L. Choyke, P. Capala, J. (2011). 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur j nucl med mol imaging, Vol.38 (11), pp. 1967-1976.  show abstract

Gijsen, M. Kramer-Marek, G. Bennett, R. Harris, A. Capala, J. Kong, A. (2011). Abstract 1530: Trastuzumab treatment induces ADAM17 and HER ligands in vivo. Cancer research, Vol.71 (8_Supplement), pp. 1530-1530.  show abstract

Kramer-Marek, G. Shenoy, N. Seidel, J. Griffiths, G. Choyke, P. Capala, J. (2011). Abstract 5284: 68Ga-radiolabeled DOTA-affibody molecule for in vivo assessment of HER2 expression with PET. Cancer research, Vol.71 (8_Supplement), pp. 5284-5284.  show abstract

Jagoda, E. Bhadrasetty, V. Lixin, L. Williams, M. Histed, S. Gabriela, K.-. Marik, J. Tinianow, J. Merchant, M. Szajek, L. Paik, C. Bottaro, D. Choyke, P. (2011). Comparison of [Zr-89] and [Br-76] labeled MetMAb, a one-armed monoclonal antibody targeting the Met receptor tyrosine kinase (Met), in human gastric carcinoma (MKN-45) and glioblastoma (U87 MG) cells and xenografts. Journal of labelled compounds & radiopharmaceuticals, Vol.54, pp. S172-S172.

Lyakhov, I. Kuban, M. Zielinski, R. Kramer-Marek, G. Capala, J. (2010). Abstract 1151: HER2- and EGFR-specific Affiprobes - Novel recombinant optical probes for cell imaging. Cancer research, Vol.70 (8_Supplement), pp. 1151-1151.  show abstract

Lyakhov, I. Zielinski, R. Kuban, M. Kramer-Marek, G. Fisher, R. Chertov, O. Bindu, L. Capala, J. (2010). HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging. Chembiochem, Vol.11 (3), pp. 345-350.  show abstract

Watson, R.P. Kramer-Marek, G. Capala, J. (2010). Instrumental neutron activation analysis of gold in mouse tissues. Abstracts of papers of the american chemical society, Vol.240.

Morgan, N.Y. Kramer-Marek, G. Smith, P.D. Camphausen, K. Capala, J. (2009). Nanoscintillator conjugates as photodynamic therapy-based radiosensitizers: calculation of required physical parameters. Radiat res, Vol.171 (2), pp. 236-244.  show abstract

Nawalany, K. Rusin, A. Kepczyński, M. Mikhailov, A. Kramer-Marek, G. Snietura, M. Połtowicz, J. Krawczyk, Z. Nowakowska, M. (2009). Comparison of photodynamic efficacy of tetraarylporphyrin pegylated or encapsulated in liposomes: in vitro studies. J photochem photobiol b, Vol.97 (1), pp. 8-17.  show abstract

Kramer-Marek, G. Kiesewetter, D.O. Capala, J. (2009). Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J nucl med, Vol.50 (7), pp. 1131-1139.  show abstract

Zielinski, R. Lyakhov, I. Jacobs, A. Chertov, O. Kramer-Marek, G. Francella, N. Stephen, A. Fisher, R. Blumenthal, R. Capala, J. (2009). Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J immunother, Vol.32 (8), pp. 817-825.  show abstract

Capala, J. Kramer-Marek, G. Lee, S.B. Hassan, M. Kiesewetter, D.O. Puri, A. Chernomordik, V. Gandjbakhche, A. Griffiths, G. Blumenthal, R. (2009). Molecular targeting of HER2 for diagnosis and therapy of breast cancer. Cancer research, Vol.69 (2), pp. 349S-349S.

Watson, R. Popelka-Filcoff, R. Kramer-Marek, G. Mackey, E.A. Spatz, R.O. Capala, J. (2009). ANYL 96-Quantitation of gold in biological tissues using neutron activation analysis. Abstracts of papers of the american chemical society, Vol.238.

Kramer-Marek, G. Kiesewetter, D.O. Martiniova, L. Jagoda, E. Lee, S.B. Capala, J. (2008). [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur j nucl med mol imaging, Vol.35 (5), pp. 1008-1018.  show abstract

Kiesewetter, D.O. Krämer-Marek, G. Ma, Y. Capala, J. (2008). Radiolabeling of HER2 specific Affibody(R) molecule with F-18. J fluor chem, Vol.129 (9), pp. 799-805.  show abstract

Lee, S.B. Hassan, M. Fisher, R. Chertov, O. Chernomordik, V. Kramer-Marek, G. Gandjbakhche, A. Capala, J. (2008). Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin cancer res, Vol.14 (12), pp. 3840-3849.  show abstract

Puri, A. Kramer-Marek, G. Campbell-Massa, R. Yavlovich, A. Tele, S.C. Lee, S.-. Clogston, J.D. Patri, A.K. Blumenthal, R. Capala, J. (2008). HER2-Specific Affibody-Conjugated Thermosensitive Liposomes (Affisomes) for Improved Delivery of Anticancer Agents. Journal of liposome research, Vol.18 (4), pp. 293-307.

Kramer-Marek, G. Kiesewetter, D.O. Martiniova, L. Rodriguez, Y. Capala, J. (2007). F-18-Z(HER2)-Affibody: A new tracer for molecular imaging of HER2-expressing tumors by PET. Molecular cancer therapeutics, Vol.6 (12), pp. 3478S-3478S.

Oyen, W. kramer-marek, G. Radioimmunotherapy for delivery of cytotoxic radioisotopes - current status and challenges. Expert opinion on drug delivery, .

Paraboschi, I. Turnock, S. Kramer-Marek, G. Musleh, L. Barisa, M. Anderson, J. Giuliani, S. Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications. Critical reviews in oncology/hematology, Vol.161, pp. 103325-?.  show abstract

Paraboschi, I. Privitera, L. Kramer-Marek, G. Anderson, J. Giuliani, S. Novel Treatments and Technologies Applied to the Cure of Neuroblastoma. Children, Vol.8 (6), pp. 482-482.  show abstract

Kastelik-Hryniewiecka, A. Jewula, P. Bakalorz, K. Kramer-Marek, G. Kuźnik, N. Targeted PET/MRI Imaging Super Probes: A Critical Review of Opportunities and Challenges. International journal of nanomedicine, Vol.16, pp. 8465-8483.  show abstract

Niedbała, M. Malarz, K. Sharma, G. Kramer-Marek, G. Kaspera, W. Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations. Oncotargets and therapy, Vol.Volume 15, pp. 437-468.


Conferences

Burley, T.Martins, C.D.Da Pieve, C.Paul, R.L.Ciobota, D.M.Smith, G.Harrington, K.Kramer-Marek, G. (2015). 89Zr-Affibody for specific detection of EGFR expression in HNSCC, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol.42, p.S247.

Martins, C.D.Da Pieve, C.Ciobota, D.M.Paul, R.L.Spinks, T.Smith, G.Kramer-Marek, G. (2015). Broadcasting the HER3 receptor status in vivo, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol.42, p.S262.

Da Pieve, C.Allott, L.Martins, C.D.Carroll, L.Paul, R.L.Aboagye, E.O.Kramer-Marek, G.Smith, G. (2015). Strategies for the development of high specific activity affibody based probes for the detection of HER3 positive tumours, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol.42, pp.S247-S248.

Price, J.M.Baker, L.C.Boult, J.K.Box, C.Kramer-Marek, G.Murray, I.Robinson, S.P.Leach, M.O. (2014). 18F-fluorodeoxyglucose (FDG) uptake is increased in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistant compared with sensitive head and neck cancer xenografts, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol.41, p.S638.

Mohd Nafi, S.N.Gijsen, M.Roxanis, I.Kramer-Marek, G.Capala, J.Kong, A. (2013). Abstract 531: HER4 cleavage and nuclear localization mediate Trastuzumab resistance in HER2-positive breast cancer., Cancer Research, Vol.73 (8_Supplement), p.531.

Wright, C.E.Jagoda, E.Cecchi, F.Bhadrasetty, V.Histed, S.Williams, M.Kramer-Marek, G.Mena, E.Rosenblum, L.Lang, L.Szajek, L.Paik, C.Choyke, P.L.Marik, J.Tinianow, J.Merchant, M.Bottaro, D.P. (2013). Developing a molecular imaging agent for Met using onartuzumab (MetMAb)., JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

Nafi, S.M.Kong, A.Gijsen, M.Kramer-Marek, G.Capala, J. (2012). Investigating the Role of HER4 in Relation to Trastuzumab Treatment and Resistance in HER2 Positive Breast Cancer, EUROPEAN JOURNAL OF CANCER, Vol.48, p.126.

Dahl, M.Bouchelouche, P.Kramer-Marek, G.Capala, J.Nordling, J.Bouchelouche, K. (2010). 857 SARCOSINE INDUCES INCREASE IN HER2/NEU EXPRESSION IN PROSTATE CANCER CELLS, European Urology Supplements, Vol.9 (2), p.272.

Dahl, M.Bouchelouche, P.Kramer-Marek, G.Capala, J.Bouchelouche, K. (2010). Effect of tumour necrosis factor (TNF) alpha on HER2/neu expression in ovarian cancer cells, EJC SUPPLEMENTS, Vol.8 (5), p.180.

Dahl, M.Bouchelouche, P.Kramer-Marek, G.Capala, J.Nordling, J.Bouchelouche, K. (2010). Sarcosine induces up-regulation of HER2/neu in androgen dependent prostate cancer cells, EJC SUPPLEMENTS, Vol.8 (5), p.179.

Capala, J.Kramer-Marek, G.Kiesewetter, D. (2010). IN VIVO QUANTIFICATION OF CHANGES IN HER2 EXPRESSION FOLLOWING THERAPEUTIC INTERVENTION, ANNALS OF ONCOLOGY, Vol.21, pp.40-41.

Kiesewetter, D.O.Kramer-Marek, G.Ma, Y.Capala, J. (2008). INOR 665-Radiolabeling of HER2 specific Affibody (R) molecule with F-18, ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, Vol.236.


Patents and patent applications

Kramer-Marek, Radiolabeled Affibody® Molecules.US 8,303,960 B2.